The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Abstract
CONTEXT: In HIV-infected patients having virologic suppression (plasma HIV RNA <50 copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been correlated with slower decay rates of latently infected cells and increased levels of viral evolution, but the clinical significance of these episodes is unknown. OBJECTIVE: To determine if HIV-infected patients with intermittent viremia have a higher risk of virologic failure (confirmed HIV RNA >200 copies/mL). DESIGN AND SETTING: Retrospective analysis of subjects in well-characterized cohorts, the AIDS Clinical Trials Group (ACTG) 343 trial of induction-maintenance therapy (August 1997 to November 1998) and the Merck 035 trial (ongoing since March 1995). PATIENTS: Two hundred forty-one ACTG 343 patients, of whom 101 received triple-drug therapy throughout the study, and a small group of 13 patients from Merck 035 having virologic suppression after 6 months of indinavir-zidovudine-lamivudine. MAIN OUTCOME MEASURES: Association of intermittent viremia (plasma HIV RNA >50 copies/mL with a subsequent measure <50 copies/mL) with virologic failure (2 consecutive plasma HIV RNA measures >200 copies/mL) in both study groups; evidence of drug resistance in 7 patients from the small (n = 13) study group with long-term follow-up. RESULTS: Intermittent viremia occurred in 96 (40%) of the 241 ACTG 343 patients of whom 32 (13%) had 2 consecutive HIV RNA values >50 copies/mL during the median 84 weeks of observation (median duration of observation after first intermittent viremia episode was 46 weeks). Of the 101 individuals receiving triple-drug therapy throughout, 29% had intermittent viremia; the proportion of episodes occurring during the maintenance period was 64% for the entire cohort and 68% for the group not receiving triple-drug therapy throughout vs 55% for those who did (P =.25). Intermittent viremia did not predict virologic failure: 10 (10.4%) of 96 patients with and 20 (13.8%) of 145 patients without intermittent viremia had virologic failure (relative risk, 0.76; 95% confidence interval [CI], 0.29-1.72). In a Cox proportional hazards model, the risk for virologic failure was not significantly greater in the ACTG 343 patients with intermittent viremia (hazard ratio, 1.28; 95% CI, 0.59-2.79). Median viral load in 10 ACTG 343 patients assessed between 24 and 60 weeks of therapy using an ultrasensitive 2.5-copies/mL detection level assay was 23 copies/mL in those with intermittent viremia vs <2.5 copies/mL in those without (P =.15). Intermittent viremia occurred in 6 of 13 patients from the small study group assessed after 76 to 260 weeks of therapy (using the 2.5-copies/mL detection level assay) and was associated with a higher steady state of viral replication (P =.03), but not virologic failure over 4.5 years of observation. Viral DNA sequences from 7 patients did not show evolution of drug resistance. CONCLUSIONS: Intermittent viremia occurred frequently and was associated with higher levels of replication (Merck 035), but was not associated with virologic failure in patients receiving initial combination therapy of indinavir-zidovudine-lamivudine (ACTG 343 and Merck 035). In this population, treatment changes may not be necessary to maintain long-term virologic suppression with low-level or intermittent viremia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Self-citationCarpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,012
Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402101 · Cited by 807
Furtado, M. R., Callaway, D. S., Phair, J. P., Kunstman, K. J., Stanton, J. L., Macken, C. A., Perelson, A. S., & Wolinsky, S. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402102 · Cited by 611
Correction: Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
(2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00020 · Cited by 502
Dornadula, G. (1999) · JAMA · doi:10.1001/jama.282.17.1627 · Cited by 463
Ramratnam, B., Mittler, J. E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C. A., Perelson, A. S., Markowitz, M., & Ho, D. D. (2000) · Nature Medicine · doi:10.1038/71577 · Cited by 452
Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391801 · Cited by 307
Self-citationO'Brien, W., Grovit-Ferbas, K., Namazi, A., Ovcak-Derzic, S., Wang, H., Park, J., Yeramian, C., Mao, S., & Zack, J. (1995) · Blood · doi:10.1182/blood.v86.3.1082.1082 · Cited by 304
Raboud, J. M., Montaner, J. S. G., Conway, B., Rae, S., Reiss, P., Vella, S., Cooper, D., Lange, J., Harris, M., Wainberg, M. A., et al. (1998) · AIDS · doi:10.1097/00002030-199813000-00008 · Cited by 259
Paredes, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.8.1123 · Cited by 235
Kempf, D. J., Rode, R. A., Xu, Y., Sun, E., Heath-Chiozzi, M. E., Valdes, J., Japour, A. J., Danner, S., Boucher, C., Molla, A., et al. (1998) · AIDS · doi:10.1097/00002030-199805000-00001 · Cited by 222
Genetic Diversity and Evolution of Retroviruses
Coffin, J. M. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-77011-1_10 · Cited by 215
Antiretroviral resistance during successful therapy of HIV type 1 infection
Martinez-Picado, J., DePasquale, M. P., Kartsonis, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Günthard, H. F., Sutton, L., Savara, A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.10948 · Cited by 209
Günthard, H. F., Frost, S. D. W., Leigh-Brown, A. J., Ignacio, C. C., Kee, K., Perelson, A. S., Spina, C. A., Havlir, D. V., Hezareh, M., Looney, D. J., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9404-9412.1999 · Cited by 201
Self-citationPredictors of optimal virological response to potent antiretroviral therapy
Powderly, W. G., Saag, M. S., Chapman, S. K., Yu, G. W., Quart, B. D., & Clendeninn, N. J. (1999) · AIDS · doi:10.1097/00002030-199910010-00009 · Cited by 192
Genetic recombination of human immunodeficiency virus
Clavel, F., Hoggan, M. D., Willey, R. L., Strebel, K., Martin, M. A., & Repaske, R. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1455-1459.1989 · Cited by 183
Grabar, S., Pradier, C., Le Corfec, E., Lancar, R., Allavena, C., Bentata, M., Berlureau, P., Dupont, C., Fabbro-Peray, P., Poizot-Martin, I., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00009 · Cited by 175
(2009) · PsycEXTRA Dataset · doi:10.1037/e566842010-001 · Cited by 165
Reijers, M. H. E., Weverling, G. J., Jurriaans, S., Wit, F. W. N. M., Weigel, H. M., ten Kate, R. W., Mulder, J. W., Frissen, P. H. J., van Leeuwen, R., Reiss, P., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)06193-5 · Cited by 154
Antiretroviral Therapy in Adults
WISE, B. V. (1996) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.1996.tb00672.x · Cited by 137
Grossman, Z., Feinberg, M. B., & Paul, W. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6314 · Cited by 132
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
Yerly, S., Kaiser, L., Perneger, T., Cone, R. W., Opravil, M., Chave, J. P., Furrer, H., Hirsch, H. H., & Perrin, L. H. (2000) · AIDS · doi:10.1097/00002030-200002180-00006 · Cited by 89
Haslett, P. A. J., Nixon, D. F., Shen, Z., Larsson, M., Cox, W. I., Manandhar, R., Donahoe, S. M., & Kaplan, G. (2000) · The Journal of Infectious Diseases · doi:10.1086/315381 · Cited by 75
Drusano, G. L., Bilello, J. A., Stein, D. S., Nessly, M. L., Meibohm, A. R., Emini, E. A., Deutsch, P., Condra, J. H., Chodakewitz, J., & Holder, D. (1998) · The Journal of Infectious Diseases · doi:10.1086/515631 · Cited by 64
Raboud, J., Rae, S. L., Hogg, R. S., Yip, B., Sherlock, C. H., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. G. (1999) · The Journal of Infectious Diseases · doi:10.1086/314998 · Cited by 42
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Hunt, P. W., Martin, J. N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., & Deeks, S. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/374786 · Cited by 852
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Metadata
- Authors
- Havlir, D. V.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-07-11
- Volume
- 286
- Issue
- 2
- Pages
- 171
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120752160
- Cited by
- 358
- References
- 30
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.